TL;DR: GLP-1 medications like Ozempic reduce appetite and compulsive cravings by quieting the brain’s reward system. For people with chronic pain, that same quieting can suppress the motivation, drive, and desire for connection that rehabilitation depends on. Pain already dims those signals. Adding a second mechanism pointing the same direction deserves careful, coordinated attention.

• GLP-1 drugs interact with dopamine and serotonin circuits, not just appetite pathways [4]

• Chronic pain already pushes the brain into a low-dopamine, low-motivation state [5]

• Polyvagal shutdown and medication-induced flatness can look identical from the outside [9]

• Integrated care means tracking motivational baseline before and after starting a GLP-1

• The drive to heal is a clinical resource. It should be protected, not inadvertently erased

I started noticing it in the small things patients said.

A woman who spent years fighting to get out of bed told me she finally could, and then added, quietly, that she no longer wanted to. Her cravings for sugar had faded. Her drive to see friends had faded with them. She’d been on a GLP-1 for weight, and something in her had gone still.

She wasn’t depressed in the way a screening tool would flag. She was flat. And flatness, in a body that lives with chronic pain, is worth paying close attention to.

What GLP-1 Drugs Are Actually Touching in the Brain

Ozempic and its cousins are widely understood as appetite drugs. They lower hunger, reduce cravings for food and alcohol. That part is real and, for many, genuinely helpful.

The part that gets less attention is where these effects actually happen.

GLP-1 receptor agonists engage circuits that link the hindbrain to the central amygdala, regulating both physical hunger and the pleasure side of eating through parallel neural pathways. They also interact with dopamine, serotonin and stress systems that shape mood, motivation, and how the body reads safety. [4]

Researchers describe the effect as a neurochemical dampening of the reward signal that drives compulsive behavior. The drugs weaken the loop between wanting something and reaching for it. For a craving that runs a person’s life, that loosening can be a genuine relief. [3]

The same mechanism reaches wider than appetite. About one in eight American adults now takes a GLP-1 drug, according to a 2025 KFF poll. [1] A subset of them report a diminished sense of enjoyment across the board, a cluster of effects the press has started calling Ozempic personality. [2]

Think of desire as a status light on the nervous system. These medications turn the light down. For many people that changes the reading without touching much underneath. For a body already braced in protection, the reading matters more than it first appears.

Key Point: GLP-1 drugs act on reward and motivation circuits, not appetite alone. For a nervous system already under strain, that distinction changes everything.

Why Chronic Pain Patients Are Especially Vulnerable to Motivation Loss

This is something I want clinicians outside pain medicine to take seriously.

Chronic pain reshapes the reward system. Persistent pain signals push the brain into what researchers call a hypodopaminergic state, a setting where the dopamine machinery that fuels motivation runs chronically low. [5]

The result is reduced drive, emotional flatness, and less pull toward the things that once felt good. Researchers call this a negative hedonic shift, a move toward more distress and less capacity for reward. [6]

This flatness is not the same as depression, and it’s not a choice. Studies of chronic low back pain found that patients were less willing to expend effort on high-reward tasks, and their pain intensity predicted that reluctance. Their depressive symptoms did not explain it. [7] The system itself was conserving energy.

💡 A body in chronic pain is already running with the desire light dimmed. It’s been dimming for months or years to protect itself.

Layer a medication that further quiets the reward system on top of that and you have two mechanisms pointing the same direction. For a patient who needs drive to move, to rehabilitate, to reconnect, that convergence deserves careful attention.

Key Point: Chronic pain already suppresses motivation at a neurochemical level. GLP-1 medications can compound that suppression, and the overlap is rarely tracked.

How the Vagus Nerve Connects Desire, Safety, and Pain

The connection runs through the vagus nerve, and it’s worth slowing down here.

Polyvagal theory describes a ladder of states the nervous system moves through. At the top sits ventral vagal safety, where you feel calm, social, capable of wanting things. Drop down and you find fight or flight. Drop further and you reach dorsal vagal shutdown, a protective freeze marked by numbness, low motivation, and withdrawal. [9]

Chronic pain pulls the system down that ladder. The body reads persistent threat and settles into a conserving, braced state. Motivation drops because the nervous system has decided that reaching out costs more than it’s worth.

Flatness and lost drive often signal a body conserving itself. That’s not the same as giving up.

When a medication broadly quiets wanting, it can feel like calm. In a nervous system already sliding toward shutdown, that quiet can look identical to the shutdown itself. The desire light goes down either way, and from the outside the two states are genuinely hard to tell apart.

⚠️ Calm and shutdown can feel similar in the body. One reflects safety. One reflects a system that’s stopped reaching. For a patient in pain, telling them apart is clinical work, not a minor detail.

Key Point: GLP-1-induced quiet and polyvagal shutdown produce overlapping signals. Distinguishing them requires someone paying attention to the whole nervous system, not just the metabolic numbers.

The Clinical Blind Spot: When Prescribers Don’t Share a Language

GLP-1 prescribing often happens far from pain care. An endocrinologist, a weight management clinic, a primary care visit. Each one sees a slice of the person.

The pain specialist rarely gets a call about a new GLP-1 prescription. The prescriber rarely asks what a patient’s baseline drive looked like before starting. So a drop in motivation gets read as expected, or incidental, when it deserves a much closer look.

That’s the cost of the biological model working alone. It treats the number on the scale and misses the nervous system attached to it.

I’m not here to pass judgment on any specific medication, and I don’t tell patients to start or stop anything. That decision belongs to them and their prescriber. My concern sits one layer up: the whole-person effects that get lost when nobody’s watching for them.

Key Point: Siloed prescribing means motivational changes go undetected. Pain specialists and GLP-1 prescribers need a shared framework for nervous system effects.

How to Tell Meaningful Desire From Compulsion

Wanting comes in different forms, and this is where the clinical work gets precise.

Some cravings run a person. The compulsive pull toward a substance or behavior that leaves them worse off. Quieting that loop can hand someone real freedom, and for many GLP-1 users that’s exactly what happens.

Other kinds of desire give a life its texture. The pull toward movement, toward connection, toward a project that matters, toward touch and closeness. That drive is the same fuel rehabilitation depends on.

The risk comes from treating all desire as one dial. When wanting gets flattened across the board, the compulsion and the meaning go quiet together. For a person in pain, losing the drive to reach for a better day isn’t a minor side effect.

💡 The goal worth aiming for: restore the capacity to want the things that heal, while loosening the grip of the things that harm.

Key Point: Compulsive craving and meaningful desire use overlapping neural circuits. Flattening one without protecting the other is a clinical risk, especially in pain patients who need motivational fuel to rehabilitate.

What Integrated Care Looks Like in Practice

The medication isn’t the problem. The person needs someone watching the whole picture.

Here is where I focus with patients navigating this:

• Name the state. When we separate the person from the flatness, the flatness becomes something we can observe and work with rather than something they are.

• Track baseline drive. We note what motivation looked like before and after the medication, so a shift gets seen rather than absorbed as normal.

• Regulate the nervous system. Polyvagal informed practices, breath work, and safe graded movement help nudge the system back up the ladder toward the state where wanting returns.

• Rebuild small wants. We rehearse reaching for tiny rewarding things, and let those small wins compound. Capacity for desire can be trained back.

• Coordinate care. When it helps, I talk with the prescriber so the metabolic goals and the nervous system goals sit in the same plan.

Therapy has a real role here. Approaches that help people reclaim dormant drive, whether somatic work or emotional awareness practices, can rebuild the reaching a person lost. The goal isn’t to override the medication. It’s to protect the drive the body needs to heal.

Key Point: Rebuilding motivational capacity is possible. It takes naming what’s happening, tracking changes over time, and using nervous system regulation tools alongside any medication plan.

Where This Trend Is Headed for Pain Care

One in eight American adults is now on one of these drugs, according to the 2025 KFF poll. [1] A meaningful share of them live with chronic pain.

Pain care has to catch up to that reality. Prescribers need to ask about motivation. Pain specialists need to ask about GLP-1 use. Both groups need a shared language for the nervous system effects that sit underneath the metabolic ones.

The research is still early. Some data links GLP-1 use to lower rates of anxiety and depression, [8] which complicates any clean story. The honest position is this: these drugs move the reward system, the direction varies by person, and chronic pain patients start from a place that makes the variation worth watching closely.

Quieting desire doesn’t heal the state that dimmed it. For a body stuck in protection, that difference decides whether pain grows quieter or louder.

If you’re living with chronic pain and feel your drive fading on one of these medications, you’re not broken, and you’re not imagining it. Your nervous system is telling you something. Bring it to someone who will listen to the whole picture, and hold onto the wanting that points you toward the life you’re working to reclaim.

Key Point: GLP-1 medications are here to stay, and their use in people with chronic pain will grow. Pain care needs to build the tools to monitor and protect motivational health alongside metabolic health.

Key Takeaways

• GLP-1 drugs interact with dopamine and serotonin circuits that govern motivation, not just appetite

• Chronic pain already produces a hypodopaminergic, low-motivation state. GLP-1 medications can compound that suppression

• Polyvagal shutdown and medication-induced flatness look nearly identical from the outside. Distinguishing them requires whole-person assessment

• Siloed prescribing means motivational changes go untracked. Pain specialists and GLP-1 prescribers need coordinated frameworks

• Meaningful desire (the pull toward movement, connection, and purpose) and compulsive craving use overlapping circuits. Flattening one risks flattening both

• Motivational capacity can be rebuilt through nervous system regulation, graded movement, and somatic-informed therapy

• If you’re on a GLP-1 and feel your drive fading, that signal deserves clinical attention, not dismissal

Frequently Asked Questions

Do GLP-1 medications cause depression?

Some studies link GLP-1 use to lower rates of anxiety and depression. [8] The picture isn’t simple. These drugs move the reward system broadly, and the direction varies by person. Emotional flatness without clinical depression is a recognized experience in a subset of users.

Why are chronic pain patients at higher risk for motivational side effects from GLP-1s?

Chronic pain pushes the brain into a hypodopaminergic state, where dopamine-driven motivation runs low. [5] Adding a medication that further quiets the reward system can compound that suppression. Two mechanisms pointing the same direction create a stronger combined effect.

What is the polyvagal connection to GLP-1 medications and pain?

Polyvagal theory describes a nervous system ladder from ventral vagal safety (calm, social, motivated) down to dorsal vagal shutdown (frozen, flat, withdrawn). [9] Chronic pain pulls people toward shutdown. GLP-1-induced flatness can look like the same state, making clinical differentiation important.

How can I tell if my reduced motivation is from pain, medication, or something else?

Tracking your baseline motivational state before starting a GLP-1, and monitoring changes after, is the most reliable approach. A pain specialist or integrated clinician can help assess whether the flatness reflects nervous system shutdown, medication effect, or another factor.

Can you rebuild motivation while staying on a GLP-1 medication?

Yes. Nervous system regulation practices, graded movement, somatic therapy, and emotional awareness work can rebuild motivational capacity alongside a GLP-1 medication plan. The goal is protecting meaningful desire while the medication addresses compulsive patterns.

Should I stop my GLP-1 medication if I notice reduced motivation?

That decision belongs to you and your prescriber. The first step is naming the change and bringing it to clinical attention. A motivated, whole-person conversation with both your prescriber and pain specialist is the right starting point, not unilateral changes.

What does integrated pain care look like for someone on a GLP-1?

It involves tracking motivational baseline, using polyvagal-informed regulation practices, coordinating between the GLP-1 prescriber and pain specialist, and using somatic or behavioral approaches to protect the drive the body needs to heal.

---

About the Author:
Dr. Zev Nevo is a double board-certified physiatrist, chronic pain survivor, and founder of the Body & Mind Pain Center. He helps people with persistent pain rebuild capacity and confidence using an evidence-based, trauma-informed mind-body rehabilitation approach.

Listen: Mind Your Body Podcast

Learn & Join: Mind-Body Rehabilitation Community

Visit the Clinic: Body & Mind Pain Center

Medical Disclaimer:
The information in this article is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article. New or changing pain symptoms should always be properly evaluated by a medical professional.

---

References

[1] Khullar, D. The Psychology of Ozempic. The New Yorker.

[2] Kaplan, S. Ozempic Might Be Making Your Team Less Driven. Here’s the Science. Inc. https://www.inc.com/soren-kaplan/ozempic-might-be-making-your-team-less-driven-heres-the-science/91367390

[3] How GLP-1s Affect Addiction. Levity. https://www.joinlevity.com/posts/how-glp1s-affect-addiction

[4] GLP-1 Receptor Agonists and Neurotransmitter Systems. International Journal of Molecular Sciences. https://www.mdpi.com/1422-0067/26/21/10743

[5] Mesolimbic Dopamine Signaling in Acute and Chronic Pain. PAIN. https://journals.lww.com/pain/fulltext/2016/06000/mesolimbic_dopamine_signaling_in_acute_and_chronic.4.aspx

[6] Negative Hedonic Shift and Reward Circuits in Chronic Pain. bioRxiv. https://www.biorxiv.org/content/10.1101/2025.01.09.632293.full.pdf

[7] Effort Discounting in Chronic Low Back Pain. PLOS ONE. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0317980

[8] Semaglutide and Mental Health Outcomes. PMC / National Institutes of Health. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363322/

[9] Porges, S. W. (2011). The Polyvagal Theory: Neurophysiological Foundations of Emotions, Attachment, Communication, and Self-regulation. W. W. Norton & Company.